Evidence map›Paper›PMID 37543938›Full record

ArticleArchives of Iranian medicine2023

Prevalence and Correlates of Polypharmacy, and Drug Utilization Pattern in a Semi-urban Population: Results from the Pars Cohort Study.

Mohammad Reza Akbari, Alireza Kamalipour, Mahsa Pakroo, Bita Mesgarpour, Hossein Poustchi, Zahra Mohammadi, Abdullah Gandomkar, Hossein Molavi Vardanjani

Open access · hybridAbstract read
In one paragraph

Article in Archives of Iranian medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Mohammad Reza AkbariMD-MPH Department, School of Medicine, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID 0000-0002-9434-1513
Alireza KamalipourHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, California, United States.ORCID 0000-0003-2916-9187
Mahsa PakrooStudent Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Bita MesgarpourNational Institute for Medical Research Development (NIMAD), Tehran, Iran.ORCID 0000-0002-4004-8493
Hossein PoustchiDigestive Disease Research Center, Digestive Research Institute, Shariati Hospital, Tehran University of medical Science, Tehran, Iran.
Zahra MohammadiDigestive Disease Research Center, Digestive Research Institute, Shariati Hospital, Tehran University of medical Science, Tehran, Iran.
Abdullah GandomkarNon-communicable Disease Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Hossein Molavi VardanjaniMD-MPH Department, School of Medicine, Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID 0000-0001-7024-8894
Shiraz University of Medical Sciences · IRUniversity of Tehran · IRNational Institute for Medical Research DevelopmentUniversity of San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough polypharmacy is considered a major predictor of irrational use of drugs, little is known about polypharmacy in developing regions. We aimed to indicate the prevalence and correlates of polypharmacy and to determine the medication profile at the population level in southern Iran.

methodsIn this cross-sectional study, we analyzed data from participants of the Pars Cohort Study (PCS) (aged above 40 years, N=9269). Polypharmacy was defined as using five or more medications concurrently. A Poisson multivariable model was applied to estimate the adjusted prevalence ratios (APRs) of various risk factors. The Anatomical Therapeutic Chemical (ATC) classification system was used for classifying medications.

resultsPrevalence of polypharmacy was 10.4%, (95% CI: 9.75; 11.08) and it was higher among females (15.0%), older adults (age≥65 years) (16.0%), and individuals with more than two chronic conditions (31%). Being female, educated, married, and not having a low socio-economic class were independently associated with a higher likelihood of polypharmacy. The most prevalent medications among female participants were sex hormones and modulators of the genital system (58.4%), drugs for acid-related disorders (14.6%), and anti-anemic preparations (13.6%,). On the other hand, males were using acid-related disorders (14.6%), anti-inflammatory and anti-rheumatic products (7.8%), and beta-blocking agents (6.3%).

conclusionThe prevalence of polypharmacy in our sample was relatively low, especially among males. Cardiovascular drugs, acid suppressants, hormonal contraceptives, and anti-anemic preparations are drug classes with the highest contribution to polypharmacy.

Indexed as

PolypharmacyAgedCohort StudiesCross-Sectional StudiesFemaleHumansMalePrevalenceUrban PopulationIrrational drug useMedication profilePolypharmacySocioeconomic status

Identifiers

PMID37543938
PMCPMC10685724
OpenAlexW4385432665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.